Christian Gastelum, MD
Endocrinology, Diabetes & Metabolism · Los Angeles, CANPI 1285782268
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $286,654 of the $320,982 with a category attached, or 89.3%. Novo Nordisk accounts for 63.1% of it on its own, with 37 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 857 payments — averaging $374.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$202K
- Lilly USA, LLC$66K
- Abbott$28K
- Sanofi-aventis U.S. LLC$11K
- Mannkind Corporation$8K
- Amgen$955
- plus $4K from 32 others
Across 47 payments — averaging $2133.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biotissue Holdings Inc.$90K
- Eli Lilly$11K
What the payments were for
- Consulting fees$8,6683%
- Speaking & faculty fees$286,65489%
- Travel & lodging$11,2964%
- Food & beverage$14,2604%
- Education$1050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 370 | $202,426 |
| Lilly USA, LLC | 115 | $66,058 |
| Abbott | 115 | $28,272 |
| Sanofi-aventis U.S. LLC | 18 | $11,318 |
| Mannkind Corporation | 51 | $8,209 |
| Amgen(2 entities) | 43 | $955 |
| Dexcom, Inc. | 20 | $637 |
| AstraZeneca(2 entities) | 14 | $442 |
| Novartis | 17 | $344 |
| Insulet Corporation | 18 | $309 |
| Boehringer Ingelheim | 7 | $186 |
| Neurocrine Biosciences, Inc. | 4 | $134 |
| Bigfoot Biomedical Inc | 2 | $126 |
| Tandem Diabetes Care, Inc. | 7 | $122 |
| Biotissue Holdings Inc. | 1 | $116 |
| Medtronic(2 entities) | 5 | $115 |
| Kvk-tech, Inc. | 2 | $112 |
| Ascendis Pharma Endocrinology Inc | 5 | $110 |
| Currax Pharmaceuticals LLC | 6 | $105 |
| Johnson & Johnson | 5 | $97 |
| IBSA Pharma Inc. | 5 | $91 |
| Ascensia Diabetes Care US Inc. | 4 | $87 |
| Corcept Therapeutics | 3 | $77 |
| BD | 1 | $77 |
| Averitas Pharma Inc. | 2 | $62 |
| Bayer | 2 | $58 |
| Antares Pharma, Inc. | 2 | $48 |
| Stryker | 1 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| BETA Bionics, Inc. | 2 | $31 |
| Rhythm Pharmaceuticals, Inc. | 1 | $31 |
| Ionis Pharmaceuticals, Inc. | 1 | $26 |
| Recordati_rare_diseases_inc. | 1 | $25 |
| Sequel Med Tech, LLC | 1 | $24 |
| Madrigal Pharmaceuticals | 1 | $20 |
| Tolmar, Inc. | 1 | $17 |
| GSK | 1 | $15 |
| Embecta Corp. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$80,468
- RYBELSUS$80,368
- LYUMJEV$24,000
- FreeStyle Libre Pro$11,268
- TZIELD$11,046
- FreeStyle Libre$8,754
- AFREZZA$7,547
- Tresiba$6,467
- FREESTYLE LIBRE 3$6,046
- Xultophy 100/3.6$3,632
- Perclose ProStyle$1,067
- DEXCOM G6 TRANSMITTER$159
- V-GO$125
- UNITY DIABETES MANAGEMENT SYSTEM$102
How this compares
$320,982 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 385 | $501,963 |
| MounjaroTirzepatide | 325 | $369,647 |
| JardianceEmpagliflozin | 123 | $137,310 |
| FarxigaDapagliflozin Propanediol | 114 | $114,134 |
| RybelsusSemaglutide | 65 | $100,540 |
| ProliaDenosumab | 48 | $81,236 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 28 | $52,936 |
| AfrezzaInsulin Regular, Human | 15 | $31,395 |
| JanuviaSitagliptin Phosphate | 37 | $29,849 |
| Tresiba Flextouch U-100Insulin Degludec | 48 | $27,321 |
| TradjentaLinagliptin | 35 | $26,839 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $22,941 |
| InvokanaCanagliflozin | 20 | $18,915 |
| LyumjevInsulin Lispro-Aabc | 11 | $16,053 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 18 | $15,309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $202,426 | $602,503450 claims |
| Lilly USA, LLCMounjaro, Lyumjev, Humalog | $66,058 | $390,085356 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $186 | $170,964169 claims |
| AstraZenecaFarxiga | $442 | $114,134114 claims |
| AmgenProlia | $955 | $81,23648 claims |
| Mannkind CorporationAfrezza | $8,209 | $31,39515 claims |
| Johnson & JohnsonInvokana | $97 | $18,91520 claims |
| Antares Pharma, Inc.Xyosted | $48 | $12,35321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Los Angeles
- Anthony HeaneyLos Angeles$588K
- Shlomo MelmedLos Angeles$177K
- Sina TebiLos Angeles$133K
- Glenn BraunsteinLos Angeles$113K
- Laurence KatznelsonLos Angeles$99K
- John CarmichaelLos Angeles$90K
- Peter ButlerLos Angeles$58K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.